Alnylam co-founder Dr. Phillip A. Sharp to retire from board effective May 8, 2025

ALNYLAM PHARMACEUTICALS, INC.

Dr. Sharp informed the board on March 3, 2025; retirement is not due to any disagreement.
He will continue to serve on Alnylam's Scientific Advisory Board after retirement.
Dr. Sharp co-founded Alnylam in 2002 and is a Nobel Prize winner for RNA splicing.
The company issued a press release on March 5, 2025 announcing the transition.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Phillip A. Sharp

Director

ALNY · ALNYLAM PHARMACEUTICALS, INC.

Effective: 2025-05-08
Filed: March 5, 2025, 6:59 PM ET

On March 3, 2025, Phillip A. Sharp, Ph.D. informed the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”) of his retirement from the Board, effective as of May 8, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Phillip A. Sharp retired as Director at ALNYLAM PHARMACEUTICALS, INC..

Action: retired
Role: Director

Exact text from the filing

On March 3, 2025, Phillip A. Sharp, Ph.D. informed the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”) of his retirement from the Board, effective as of May 8, 2025.

View on SEC.gov

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001178670-25-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.